A New Study Finds AGT “CC” Genotype Is More Common in Elite Power Athletes, but Not in Endurance Sports, Reports Journal of Strength and Conditioning Research
Philadelphia, Pa. (September 25, 2013) – A specific gene variant is more frequent among elite athletes in power sports, reports a study in the October issue of The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association (NSCA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
A “functional polymorphism” of the angiotensiogen (AGT) gene is two to three times more common in elite power athletes, compared to nonathletes or even elite endurance athletes, according to the new research by Paweł Cięszczyk, PhD, of University of Szczecin, Poland, and colleagues. They write, “[T]he M23T variant in the AGT may be one of the genetic markers to investigate when an assessment of predisposition to power sports is made.”
Gene Variant More Common in Elite Power Athletes…
The researchers analyzed DNA samples from two groups of elite Polish athletes: 100 power-oriented athletes, from sports such as power-lifting, short-distance runners, and jumpers; and 123 endurance athletes, such as long-distance runners and swimmers and rowers. All athletes competed at the international level—eg, World and European Championships, World Cups, or Olympic Games. A group of 344 nonathletes were studied for comparison.
The analysis focused on the genotype of the M235T polymorphism of the gene AGT. “Polymorphisms” are genes that can appear in two different forms (alleles). A previous study found that the “C” allele of the AGT gene (as opposed to the “T” allele) was more frequent among elite athletes in power sports.
The genetic tests found that elite power athletes were more likely to have two copies of the C allele—in other words, they inherited the C allele from both parents. This “CC” genotype was found 40 percent of the power athletes, compared to 13 percent of endurance athletes and 18 percent of nonathletes.
Power athletes were three times more likely to have the CC genotype compared to endurance athletes, and twice as likely compared to nonathletes. At least one copy of the C allele was present in 55.5 percent of power athletes, compared to about 40 percent of endurance athletes and nonathletes.
…But Functional Significance Not Yet Clear
In a further analysis, the researchers found no differences in genotype between “top-elite” athletes who had won medals in international-level competition, compared to elite-level athletes who were not medalists.
The new study is the first to replicate previous, independent research showing an increased rate of the CC genotype of the AGT gene among power athletes on Spanish national teams. That study also found about a 40 percent prevalence of the CC genotype among elite power athletes.
The AGT gene is part of the renin-angiotensin system, which plays essential roles in regulating blood pressure, body salt, and fluid balance. There are several possible ways in which the CC genotype might predispose to improved power and strength capacity—including increased production of angiotensin II, which is crucial for muscle performance. However, the researchers emphasize that the “functional consequences” of the M235T polymorphism remain to be determined.
The study contributes to the rapidly evolving body of research on genetic factors related to exercise, fitness, and performance—which may one day have implications for identification and training of potential elite-level athletes. Dr Cięszczyk and coauthors conclude, “Identifying genetic characteristics related to athletic excellence or individual predisposition to types of sports with different demands (power or endurance oriented) or even sport specialty may be decisive in recognizing athletic talent and probably will allow for greater specificity in steering of sports training programs.”
About The Journal of Strength and Conditioning Research
The editorial mission of The Journal of Strength and Conditioning Research (JSCR) is to advance the knowledge about strength and conditioning through research. A unique aspect of this journal is that it includes recommendations for the practical use of research findings. While the journal name identifies strength and conditioning as separate entities, strength is considered a part of conditioning. The journal wishes to promote the publication of peer-reviewed manuscripts which add to our understanding of conditioning and sport through applied exercise science. The JSCR is the official research journal of the National Strength and Conditioning Association.
About The National Strength and Conditioning Association
The National Strength and Conditioning Association was founded in 1978 with 76 strength coaches from across the country with the common desire to network, collaborate and unify the profession of strength and conditioning. Since its inception, the NSCA has grown to nearly 30,000 members in 72 countries and become the leader in the research and education of strength and conditioning professionals. Take a tour of the NSCA’s past and learn more about how it became the institution that it is today.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health’s customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of €3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348